Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals focuses on creating transformative medicines for serious diseases, with a special emphasis on specialty markets. The company's research and development efforts have been successful, leading to the launch of four medicines for cystic fibrosis that funds the company's R&D projects.

Vertex Pharmaceuticals: Pioneering Scientific Advances To Tackle Serious Diseases

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Vertex (VRTX) Q4 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Susie Lisa – Senior Vice President-Investor Relations Reshma Kewalramani – Chief Executive Officer and President Stuart Arbuckle – Chief Operating Officer Charlie Wagner – Chief Financial Officer Conference Call Participants Salveen Richter – Goldman Sachs Geoff Meacham – Bank of America Phil Nadeau – Cowen Liisa Bayko – Evercore ISI David Risinger – SVB Robyn Karnauskas – Truist Mohit Bansal – Wells Fargo Jessica Fye – JPMorgan Evan Seigerman – BMO Capital Markets Operator Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter and Full Year 2022 Conference Call. All participants will be in a listen-only mode.

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2022 Earnings Call Transcript

Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates

Vertex Pharmaceuticals offered an upbeat look for 2023 sales after reporting an earnings beat and in-line sales. But VRTX stock was muted.

Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2022 and provided full year 2023 financial guidance. “Outstanding execution across the company resulted in another year of strong revenue growth as well as acceleration of both the research and clinical-stage pipeline,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.

Vertex Reports Fourth Quarter and Full Year Financial 2022 Results

Chimerix

Genfit - ADR

Harmony Biosciences Holdings

iTeos Therapeutics, Inc.

Regeneron Pharmaceuticals

Selecta Biosciences

While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.

The 7 Best Biotech Stocks to Buy for February 2023

Amgen

Exact Sciences

Gilead Sciences

GlaxoSmithKline

Immunocore Holdings

Eli Lilly

Moderna

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

Dollar General

Enterprise Products Partners

All three of these stocks performed well as the market fell in 2022.

3 Top Stocks to Buy If There Is a Market Pullback

Palo Alto Networks

PayPal

The growth-focused Nasdaq 100 is home to three exceptional deals.

3 Nasdaq 100 Stocks to Buy Hand Over Fist in February

If these indicators were in a Magic 8 Ball, they'd probably say, "Ask again later."

Is a Recession on the Way? Here's What the Top 7 Indicators Say.

AbbVie

These stocks are growing steadily and have a solid history of enriching shareholders.

2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade

Amazon

MercadoLibre

Going with these stocks should be an easy decision.

3 No-Brainer Stocks to Buy in February

Alphabet

The bulls could be about to take over again. And these stocks are poised to be big winners.

A New Bull Market Could Arrive in February: 3 Stocks to Buy Now

CVS Health

Disney

Duke Energy

Fiserv

PepsiCo

Philip Morris

S&P Global

The fourth quarter 2022 earnings season continues to be subpar for the S&P 500.

10 Biggest Companies Reporting Earnings in the Second Week of Feb 2023

Agnico Eagle Mines

BHP Billiton

Baker Hughes Co

Caterpillar

Crocs

Halliburton

National Instruments

Schlumberger

Triton International

Ulta Beauty

United Rentals

The best stocks to watch often hail from the top-ranked industries. Here's a look 11 stocks, including VRTX ad ULTA, that fit that bill.

This Clue Helps Spot The Best Stocks To Watch, Including These 11

Catalyst Pharmaceuticals

iShares Nasdaq Biotechnology ETF

Inspire Medical Systems Inc

Novocure

Revance Therapeutics

Teva Pharmaceutical

Zai Lab Ltd.

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride

Apple

Axcelis Technologies

Pfizer

Stellantis N.V. 

Teck Resources

Taiwan Semiconductor Manufacturing

Investors are scurrying to find stocks to buy as the market stages a strong uptrend this year. Of course, people make money when prices go up.

7 Cream-of-the-Crop Stocks to Buy Today

Baidu

Axon Enterprise

Visteon

BP and Chinese search leader Baidu lead this weekend's watch list of 5 stocks near buy points with strong growth opportunities. The post BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential appeared first on Investor's Business Daily.

BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential

Johnson & Johnson

Their products will enjoy strong demand regardless of what happens with the economy.

3 Smart Stocks to Buy if a Recession Is on the Way

News for Vertex Pharmaceuticals Stock (VRTX)